Zurich Cantonal Bank
ZNTL icon

Zurich Cantonal Bank’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Zurich Cantonal Bank’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-7,809
Closed -$31.9K – 2672
2024
Q2 		$31.9K Sell
7,809
-7,809
-50% -$87.2K ﹤0.01% 2573
2024
Q1 		$246K Buy
15,618
+7,809
+100% +$107K ﹤0.01% 1937
2023
Q4 		$118K Hold
7,809
– – ﹤0.01% 2365
2023
Q3 		$157K Hold
7,809
– – ﹤0.01% 2121
2023
Q2 		$220K Buy
7,809
+1,886
+32% +$45.2K ﹤0.01% 1870
2023
Q1 		$102K Sell
5,923
-369
-6% -$7.47K ﹤0.01% 2271
2022
Q4 		$127K Hold
6,292
– – ﹤0.01% 2123
2022
Q3 		$136K Hold
6,292
– – ﹤0.01% 1994
2022
Q2 		$177K Buy
6,292
+5,923
+1,605% +$157K ﹤0.01% 1869
2022
Q1 		$17K Sell
369
-659
-64% -$35.5K ﹤0.01% 2685
2021
Q4 		$86K Sell
1,028
-85
-8% -$6.58K ﹤0.01% 2576
2021
Q3 		$74K Buy
1,113
+15
+1% +$865 ﹤0.01% 2484
2021
Q2 		$58K Buy
1,098
+122
+13% +$6.53K ﹤0.01% 2422
2021
Q1 		$42K Buy
+976
New +$42K ﹤0.01% 2441

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Zurich Cantonal Bank's ZNTL Position: Q3 2024 in Review

Zurich Cantonal Bank sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2024, closing a stake of 7,809 shares — an estimated $31.9K sold.

Zurich Cantonal Bank first reported a position in ZNTL in Q1 2021 and held it in 14 quarters. The position peaked at $246K in Q1 2024. 136 funds tracked by Wall St. Rank hold ZNTL as of Q3 2024.

  • Zurich Cantonal Bank reported no remaining Zentalis Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Zurich Cantonal Bank sold 7,809 Zentalis Pharmaceuticals shares in Q3 2024, an estimated $31.9K.
  • Zurich Cantonal Bank first reported a position in Zentalis Pharmaceuticals in Q1 2021 and held it in 14 quarters.
  • Zurich Cantonal Bank's Zentalis Pharmaceuticals position peaked at $246K in Q1 2024.
  • 136 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2024.

Based on Zurich Cantonal Bank's 13F filing for Q3 2024, filed 8 Nov 2024.